System Maintenance Notice

Please note that maintenance work is scheduled between 4 AM and 5 AM - CET. During this time, you may experience reduced performance. Thanks for your patience.

Thomas J Ettrich is an expert in Oncology at University Hospital Ulm (Germany). As of October 2026, ScienceLeadR ranks Thomas J Ettrich in the top 1% of experts worldwide for Carcinoma and Gastrointestinal Neoplasms. Thomas J Ettrich has authored 270 publications, the most recent in 2026, and is an investigator in 49 clinical trials, 17 of them ongoing. SLR score: 1,535 (community average: 125). How the SLR is computed.

LeadR Profile

Thomas J Ettrich University Hospital Ulm Germany
1 535 ScienceLeadR Reputation 1535

Unlock

Register Login
Network Map

Oncology

Subspecialties: Gastroenterology - Hepatology - Biochemistry

Full career – Last 3 years

Main Topics

Publications and Clinical Studies

Publications – Clinical Studies

Profile data updated on

Expert Rankings

Top experts on the MeSH terms this expert works on

Organizations

Career arc: 2006 - 2026
Source: PubMed

University Hospital Ulm

Publications Synthesis

Sources: PubMed, OpenAlex

Number : 270

Citations

Citations: 4 035 1st author: 45 Last author: 18 Unique author: 2

Main journals

J Clin Oncol 66
Ann Oncol 42
Z Gastroenterol 24
BMC Cancer 8
ESMO Open 8

Best Journals

J Clin Oncol 48
Ann Oncol 28
Lancet Gastroenterol Hepatol 3

Breakdown by type

Click a legend label to hide or show it in the chart.

Latest Publications

5 most recent indexed articles

Source: Pubmed

Title Journal Year Citations
Quality of life in patients with RAS wild-type metastatic colorectal cancer treated mFOLFOXIRI + panitumumab versus FOLFOXIRI: A prespecified secondary analysis of the phase II VOLFI AIO-KRK 0109 trial.
PMID 42743885 — skin, quality of life, antibodies, neoplasms, panitumumab, therapeutics, colorectal neoplasms		Eur J Cancer20260
Pathologic Complete Response to Neoadjuvant Dual Checkpoint Blockade with Durvalumab Plus Tremelimumab in Advanced-Stage HCC: A Case Report.
PMID 42668870 — neoplasms, liver, hepatectomy, immunotherapy, therapeutics		J Hepatocell Carcinoma20260
Durvalumab and tremelimumab, with or without lenvatinib, combined with transarterial chemoembolisation in participants with embolisation-eligible hepatocellular carcinoma (EMERALD-3): a global, randomised, open-label, sponsor-blinded, phase 3 study.
PMID 42636832 — carcinoma, hepatocellular, progression-free survival, neoplasms, drug-related side effects and adverse reactions, therapeutics		Lancet Oncol Top journal20260
Computed Tomography-Based Assessment of Sarcopenia and Disease Progression in Pancreatic Ductal Adenocarcinoma: A Radiomics and Machine Learning Approach.
PMID 42325217 — muscles, tomography, neoplasms, adenocarcinoma, disease progression, machine learning, sex, muscle, skeletal, learning, forests, sarcopenia		Gastroenterology Res20260
Plasma PlGF as a Potential Biomarker in Ramucirumab-Based Second-Line Therapy for Advanced Gastroesophageal Adenocarcinoma: Exploratory Biomarker Analysis from the Phase II Part of the RAMIRIS Trial.
PMID 42266015 — neoplasms, adenocarcinoma, biomarkers, tryptases, therapeutics, stomach neoplasms, plasma		Int J Cancer20260

Clinical Studies 49

Sources: ClinicalTrials, EU CTIS

Synthesis

Principal Investigator: 3

By phase:

Phase 2 26
Phase 3 14
Phase 1/Phase 2 4
Phase 2/Phase 3 3
N/A 1
Phase 1 1

By status:

Completed 22
Recruiting 12
Unknown 5
Active not recruiting 4
Not yet recruiting 3
Suspended 1
Terminated 1
Withdrawn 1

By type:

Interventional 48
Observational 1

By Monocentric/Multicentric:

monocentric 10
multicentric2to4 6
multicentric5to9 4
multicentricup10 29

Main Topics

Cohort/Consortium Investigators 1

Ongoing Clinical Trials

17 ongoing trials started since 2021, where this expert is an investigator

Source: ClinicalTrials

Study Phase Status Start
Paclitaxel Ramucirumab and Tislelizumab Switch Maintenance in Advanced HER2 negative and PD L1 TAP Score of 5 or More Advanced Gastroesophageal Adenocarcinoma
NCT07763171 — leucovorin, quality of life, progression-free survival, paclitaxel, clinical deterioration, adenocarcinoma, disease progression, drug therapy, oxaliplatin, maintenance, fluorouracil, therapeutics, capecitabine, chemotherapy		Phase 3Not yet recruiting2026
A trial to learn how well sonesitatug vedotin and capecitabine with or without rilvegostomig work and how safe they are in adults with cancers of the stomach and esophagus
2024-519787-40-00 — stomach, esophagus, esophagogastric junction, neoplasms, adenocarcinoma, work, therapeutics, esophageal neoplasms, capecitabine, stomach neoplasms		Phase 3Not yet recruiting2026
ZANGEA Phase II Study of Zanidatamab in Combination with Pembrolizumab and Chemotherapy in HER2 and PD L1 Positive Metastatic Gastroesophageal Adenocarcinoma (GEA) Patients
2025-522718-22-00 — adenocarcinoma, drug therapy, chemotherapy		Phase 2Recruiting2025
Visugromab nivolumab and lenvatinib compared to double placebo and lenvatinib in unresectable or metastatic hepatocellular carcinoma post anti PD (L)1 failure
2025-520675-86-00 — carcinoma, hepatocellular, safety, liver, nivolumab, therapeutics, child, carcinoma		Phase 2Recruiting2026
Prospective placebo controlled clinical trial with Aconite Pain Oil in oncological patients under going chemotherapy to prevent chemotherapy induced polyneuropathy (CIPN) to re duce symptoms typical of CIPN and to improve the quality of life of patients with CIPN
2022-502889-24-00 — quality of life, pain, drug therapy, signs and symptoms, polyneuropathies, chemotherapy		Phase 3Recruiting2024

LeadR Networks

Main global connection map

Sources: PubMed, OpenAlex, ClinicalTrials, EU CTIS